Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25327731 | 1.00 | PRMT5 (0.41) | PRMT5RIPK1WDR77HRH3SIGMAR1 | |
| SCHEMBL25328455 | 0.95 | PRMT5 (0.40) | PRMT5RIPK1WDR77HRH3 | |
| SCHEMBL25328458 | 0.95 | PRMT5 (0.40) | PRMT5RIPK1WDR77HRH3 | |
| SCHEMBL25326948 | 0.86 | RIPK1 (0.42) | PRMT5RIPK1HRH3P2RX7POLB | |
| SCHEMBL25326953 | 0.86 | RIPK1 (0.42) | PRMT5RIPK1HRH3P2RX7POLB | |
| SCHEMBL25328181 | 0.85 | TACR1 (0.37) | PRMT5RIPK1WDR77 | |
| SCHEMBL30523039 | 0.85 | TACR1 (0.37) | PRMT5RIPK1WDR77 | |
| SCHEMBL25328594 | 0.82 | PRMT5 (0.39) | PRMT5RIPK1WDR77SIGMAR1P2RX7 | |
| SCHEMBL25327211 | 0.82 | PRMT5 (0.39) | PRMT5RIPK1WDR77SIGMAR1P2RX7 | |
| SCHEMBL30522989 | 0.82 | TACR1 (0.38) | PRMT5RIPK1WDR77SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | PRMT5 2082/4885RIPK1 4782/4885WDR77 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.